| News From Transplant Week of January 6, 2002 / Vol. 3 No. 1 |
|
Tests Proposed of New Therapy for Chronic Transplant Rejection |
|
AtheroGenics, Inc. announced that it had asked the U.S. Food
and Drug Administration for permission to initiate clinical trials
of AGI-1096, a novel, oral drug for the prevention of organ transplant
"Because of the unique properties of this compound, we are encouraged by the prospect of bringing forward a new therapy for patients at risk for chronic transplant rejection," said Dr. Russell M. Medford, president of AtheroGenics. Medford said AGI-1096 is
an anti-inflammatory agent that both diminishes the transplant
response to inflammation, a contributing factor in chronic rejection,
and directly protects the blood vessels to the transplanted organ,
potentially providing a unique and complementary therapy to existing
immunosuppressants. Other sources: AtheroGenics |
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
